Form 4: Regeneron Director Joseph Goldstein Reports Equity Grants

Regeneron Pharmaceuticals director Joseph L. Goldstein reported the acquisition of 155 restricted stock units and 1,962 non-qualified stock options.

Summary

• Joseph L. Goldstein, a Director at Regeneron Pharmaceuticals, Inc. (REGN), reported changes in his beneficial ownership.
• On January 2, 2026, Goldstein acquired 155 shares of common stock, which are time-based vesting restricted stock units (RSUs).
• Following this transaction, Goldstein directly beneficially owns 6,703 shares of common stock.
• On the same date, he also acquired 1,962 non-qualified stock options with an exercise price of $772.76.
• These stock options have an expiration date of January 2, 2036.
• A portion of the stock options will become exercisable on the date of the Issuer's first annual meeting of shareholders following the grant date, with the remainder exercisable on the first anniversary of the grant date.
• The acquisition price for both the RSUs and stock options was $0.0, indicating they were grants.

Sentiment

Score: 7

Explanation: The filing is a routine disclosure of equity grants to a director, which is a standard practice for aligning interests and incentivizing long-term performance. It does not contain information that would significantly alter the company's outlook.

Positives

• Director Joseph L. Goldstein received equity grants, aligning his interests with long-term shareholder value.
• The grants include both restricted stock units and stock options, providing a balanced incentive structure.
• The stock options have a 10-year expiration, offering a long-term incentive for performance.

Future Outlook

The vesting schedule for the stock options indicates future exercisability, aligning with long-term retention and performance incentives for the director.

Industry Context

Equity grants to directors and executives are a standard practice in the pharmaceutical and biotechnology industry, aiming to incentivize long-term performance and align management interests with shareholder returns. Regeneron's grants are consistent with typical compensation structures for directors in publicly traded companies, especially in a high-growth sector like pharmaceuticals.

Comparison to Industry Standards

• The structure of granting both restricted stock units (RSUs) and stock options is a common practice in the pharmaceutical industry for executive and director compensation, similar to companies like Pfizer or Merck.
• The exercise price of $772.76 for the stock options is based on the market price at the time of grant, which is standard.
• The 10-year expiration period for stock options is also typical for long-term incentive plans in the sector.

Related Party Transactions

• The equity grants to Director Joseph L. Goldstein are part of standard director compensation and are disclosed as such.

Stakeholder Impact

• Shareholders: The grants align the director's interests with long-term shareholder value.

Next Steps

• A portion of the stock options will become exercisable on the date of Regeneron's first annual meeting of shareholders following the grant date.
• The remainder of the stock options will become exercisable on the first anniversary of the grant date.

Key Dates

Recommendation

This Form 4 filing reports routine equity grants to a director and does not contain new material information that would warrant a change in investment recommendation. It reflects standard compensation practices aimed at aligning director interests with long-term company performance. Investors should consider this as part of ongoing corporate governance and compensation disclosures, but it's not a catalyst for a buy or sell decision on its own.

Keywords

Regeneron Pharmaceuticals, REGN, Joseph L. Goldstein, Form 4, insider transaction, stock options, restricted stock units, equity grant, director compensation